secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0001193125-24-075908
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio to acquire AnHeart Therapeutics in all-stock merger; AnHeart holders to own ~33%
--------------------------------------------------------------------------------

- Nuvation Bio to acquire AnHeart via merger; will issue ~128.7M shares of Class A common stock and ~2.9M warrants to AnHeart securityholders.
- AnHeart shareholders will own about one-third of combined company on fully-diluted basis; Nuvation Bio shareholders retain two-thirds.
- Board expands from seven to nine; Junyuan Jerry Wang (Ph.D.) and Xiangmin Cui (Ph.D.) appointed as new directors.
- Voting agreements: holders of ~90% of AnHeart shares and Nuvation Bio CEO David Hung (~27% of Nuvation shares) commit to support deal.
- Lock-up for 90% of AnHeart shareholders restricts transfer of up to 20% of shares until December 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524075908/0001193125-24-075908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524075908/d785312d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-075908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer